2.25
0.00%
Close of 9 Nov 2026, in PLN
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nanogroup
Its shares trade on GPW under the ticker NNG.WA. It has been listed since 21 December 2017. In the fiscal year to 31 December 2024, it reported revenue of PLN 2,100 and a net loss of PLN 5.2m. At that date it held total assets of PLN 19.9m and shareholders' equity of PLN 15.2m.
NanoGroup SA engages in the medical research and development. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2017-12-21. The firm focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 21 Dec 2017
- Website
- nanogroup.eu ↗
Leadership
Pay as last reported
- Mr. Jerzy GarlickiChairman of the Supervisory Board, since 2021PLN 6,000
- Mr. Przemyslaw MazurekPresident of the Management Board, since 2017PLN 9,000
- Mr. Piotr MierzejewskiVice-President of the Management Board
- Mr. Stefan BoguslawskiMember of the Management Board
- Prof. Tomasz CiachMember of the Management Board, FounderPLN 170,000
- Mr. Lukasz GolebiewskiIndependent Member of the Supervisory Board
- Mr. Rafal PlokarzIndependent Member of the Supervisory Board
- Mr. Jose ArrietaMember of the Supervisory Board
- Mr. Robert DziulowskiMember of the Supervisory BoardPLN 3,000
- Mr. Artur OlenderMember of the Supervisory BoardPLN 7,500
- Dr. Tadeusz WesolowskiMember of the Supervisory BoardPLN 9,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NanoVelos optimizes oncologic medicine performance through advanced drug delivery systems.
- NanoSanguis develops artificial blood for accident victims and organ preservation systems.
- NanoThea detects cancer cells in early stages using innovative technology.
Weaknesses
- NanoGroup SA's IPO was on 21 December 2017, a relatively recent listing.
- The company focuses on Warsaw, Woj. Mazowieckie, limiting geographic expansion.
- NanoGroup SA's business is solely in the Health Care sector, increasing sector-specific risk.
Opportunities
- NanoVelos can expand into new markets for drug delivery systems.
- NanoSanguis has potential for growth in organ preservation technology.
- NanoThea can leverage early cancer detection for global health initiatives.
Threats
- NanoGroup SA faces competition from established biotech firms in Poland.
- The Health Care sector is subject to regulatory changes affecting R&D.
- NanoGroup SA's reliance on Warsaw may hinder international partnerships.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.